Pharming Group's Investor Conference Participation
Pharming Group N.V. (NASDAQ: PHAR) is gearing up to engage with investors at significant upcoming conferences. The management team is scheduled to participate in these vital gatherings, emphasizing their ongoing commitment to communication with stakeholders and the wider investment community.
Canaccord Genuity Annual Growth Conference
One of the highlights of Pharming's participation is at the Canaccord Genuity 45th Annual Growth Conference. This event will take place in Boston and is known for attracting influential members of the investment community. Fabrice Chouraqui, Pharming's Chief Executive Officer, will present at this conference on a pivotal date.
Presentation Details
During his presentation on August 12, Chouraqui aims to discuss Pharming's innovative pipeline and their strategies for patient care. This conference is an excellent opportunity for investors to gain insights into the company's future direction and initiatives.
Engaging with Investors
Pharming Group strongly believes in maintaining open lines of communication with its investors. The company encourages attendees to schedule one-on-one meetings to discuss any queries and to explore opportunities for collaboration. Interested individuals can reach out to Pharming's Investor Relations team for more details.
About Pharming Group N.V.
Pharming Group N.V. is dedicated to making a significant impact in the lives of patients who suffer from rare and debilitating diseases. The company is focused on developing and commercializing novel biopharmaceuticals and small molecules. With its headquarters in Leiden, the Netherlands, Pharming operates in over 30 markets globally, ensuring access to its critical therapies across various regions.
Innovative Products on the Market
The company has successfully developed innovative medicines that cater to complex medical needs, paving the way for hope and improved outcomes for patients. Their commitment to research and development drives the continuous evolution of their product offerings, aiming to address unmet medical needs.
Commitment to Patient Care
Pharming remains unwavering in its mission to support patients through effective treatment options. The company collaborates with healthcare providers and patient advocacy groups to ensure that therapies are not only effective but also accessible. Their initiatives focus on building awareness and providing comprehensive education regarding their products.
Contact Information for Investor Relations
For more details regarding Pharming's investor engagements or inquiries, interested parties can reach out directly. The contact person for Investor Relations is Michael Levitan, who can provide further insights and support regarding ongoing and future initiatives.
Frequently Asked Questions
What is Pharming Group's stock ticker symbol?
The stock ticker symbol for Pharming Group is PHAR, which is listed on NASDAQ.
Where is Pharming Group headquartered?
Pharming Group is headquartered in Leiden, the Netherlands.
What is the focus of Pharming Group?
Pharming Group focuses on developing biopharmaceuticals for rare and debilitating diseases, aiming to improve patient outcomes globally.
Who is Pharming's CEO?
The Chief Executive Officer of Pharming Group is Fabrice Chouraqui.
How can investors contact Pharming Group?
Investors can contact Pharming Group's Investor Relations at investor@pharming.com for inquiries or to schedule meetings.
